VANCOCIN HYDROCHLORIDE Drug Patent Profile
Which patents cover Vancocin Hydrochloride, and what generic alternatives are available?
Vancocin Hydrochloride is a drug marketed by Ani Pharms and Steriscience and is included in six NDAs.
The generic ingredient in VANCOCIN HYDROCHLORIDE is vancomycin hydrochloride. There is one drug master file entry for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vancocin Hydrochloride
A generic version of VANCOCIN HYDROCHLORIDE was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17th, 1987.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VANCOCIN HYDROCHLORIDE?
- What are the global sales for VANCOCIN HYDROCHLORIDE?
- What is Average Wholesale Price for VANCOCIN HYDROCHLORIDE?
Summary for VANCOCIN HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| Clinical Trials: | 35 |
| Patent Applications: | 898 |
| DailyMed Link: | VANCOCIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for VANCOCIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Alexander Flannery | Phase 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Memorial University of Newfoundland | Phase 3 |
Pharmacology for VANCOCIN HYDROCHLORIDE
| Drug Class | Glycopeptide Antibacterial |
US Patents and Regulatory Information for VANCOCIN HYDROCHLORIDE
Vancocin Hydrochloride Market Dynamics, Patent Exclusivity, and Financial Trajectory
Vancocin hydrochloride is the former U.S. brand of oral vancomycin hydrochloride capsules used primarily for treatment of Clostridioides difficile-associated diarrhea and enterocolitis. Its commercial trajectory illustrates the rapid erosion of a branded anti-infective after generic entry: ViroPharma generated substantial revenue before competition, but sales declined sharply once FDA-approved generic capsules reached the market. The product no longer has a meaningful branded growth profile, and its commercial value is concentrated in generic manufacturing, hospital and specialty-pharmacy distribution, and supply reliability.
What is Vancocin hydrochloride and how is it used?
Vancocin hydrochloride contains vancomycin hydrochloride, a glycopeptide antibacterial. The oral formulation is poorly absorbed systemically and is used for infections in the gastrointestinal tract, particularly C. difficile infection. It is distinct from intravenous vancomycin, which is used for systemic infections.
| Attribute | Vancocin hydrochloride |
|---|---|
| Active ingredient | Vancomycin hydrochloride |
| Dosage form | Oral capsules; historically also oral solution preparation |
| Original U.S. brand | Vancocin |
| Primary indication | C. difficile-associated diarrhea and enterocolitis |
| Original U.S. commercial owner | ViroPharma Inc. |
| Current market structure | Generic-dominated |
| FDA pathway for competitors | Abbreviated New Drug Application, or ANDA |
| Main competitive products | Generic vancomycin hydrochloride capsules; fidaxomicin; compounded oral vancomycin |
| Key commercial issue | Price erosion and substitution after generic entry |
Vancocin did not compete only with other vancomycin products. Fidaxomicin, marketed as Dificid by Merck, competes directly in C. difficile treatment, particularly where recurrence risk and guideline preference support use of a narrower-spectrum agent.
When did Vancocin hydrochloride lose exclusivity?
Vancocin lost practical market exclusivity when FDA-approved generic oral vancomycin capsules entered the U.S. market in the early 2010s. The commercial erosion was driven by generic substitution rather than by a single later patent expiration date.
ViroPharma had maintained a commercially valuable position through product ownership, regulatory strategy, manufacturing controls and market familiarity. That position weakened after FDA approved ANDAs for generic oral vancomycin capsules. Generic entrants did not need to repeat full clinical development because oral vancomycin capsules were approved through the ANDA pathway.
The relevant exclusivity sequence was:
| Period | Market event | Commercial effect |
|---|---|---|
| 2004 | ViroPharma acquired Vancocin from Baxter | ViroPharma obtained U.S. commercial rights |
| 2006 | FDA approved Vancocin capsules for an expanded C. difficile indication | Broader labeled market and stronger brand positioning |
| Late 2011 to 2012 | FDA-approved generic oral vancomycin capsules became available | Brand price and volume pressure increased |
| 2012-2013 | Generic substitution expanded | Vancocin revenue declined materially |
| Post-2013 | Market became primarily generic | Brand franchise lost strategic importance |
| 2014 | ViroPharma was acquired by Shire | Vancocin became a legacy product within a larger portfolio |
The exact commercial timing varied by generic manufacturer and distribution channel. FDA approval of an ANDA does not always mean immediate nationwide launch, because launch timing can depend on manufacturing readiness, litigation, supply agreements and commercial pricing.
What patents protected Vancocin hydrochloride?
The most important historical protection for Vancocin was not limited to a single active-ingredient patent. The product was a known antibiotic, and its competitive position depended on a combination of formulation, manufacturing, regulatory and commercial protections.
Formulation patents
Patents associated with Vancocin-related oral products addressed matters such as:
- Vancomycin capsule composition.
- Stabilization and handling of vancomycin hydrochloride.
- Capsule dosage forms.
- Pharmaceutical formulations suitable for oral administration.
- Manufacturing and quality-control processes.
A notable historical patent family associated with ViroPharma and Vancocin included U.S. Patent No. 6,395,752. Patent scope and enforceability depended on the claims, prosecution history, terminal disclaimers, maintenance fees and any later court or Patent Trial and Appeal Board actions. Patent status must be evaluated by claim and jurisdiction rather than by the existence of a product-related patent alone.
Method-of-use patents
Vancocin also benefited from indication-specific regulatory positioning. The FDA's approval for C. difficile-associated diarrhea and enterocolitis supported product differentiation, but method-of-use protection was not sufficient to prevent ANDA competition where generic applicants could use a permissible label strategy.
A generic applicant may seek approval with a full label, a section VIII statement for a patented use, or a Paragraph IV certification challenging listed patent claims. For oral vancomycin, the practical barrier to entry was reduced because the underlying active ingredient was well established and the product could be developed through an ANDA.
Manufacturing and regulatory barriers
Manufacturing requirements remain relevant even after patent expiry. Oral vancomycin products require:
- Consistent potency and content uniformity.
- Control of impurities and degradation products.
- Validated dissolution performance.
- Reliable supply of pharmaceutical-grade vancomycin hydrochloride.
- Compliance with current good manufacturing practice requirements.
- Demonstration of bioequivalence or equivalent pharmaceutical performance under the applicable FDA standards.
These barriers can limit the number of active suppliers. They do not, however, recreate branded exclusivity. A manufacturing disruption can produce temporary price increases or allocation problems, but it does not normally restore the former Vancocin pricing structure.
What was the Orange Book status of Vancocin?
The FDA Orange Book historically listed Vancocin hydrochloride capsules and related patents or exclusivity information applicable to the product. The commercial significance of those listings depended on whether the patents were active, whether the generic applicant filed a Paragraph IV certification, and whether litigation triggered a 30-month stay.
The Orange Book remains the primary U.S. reference for:
- Approved reference listed drug status.
- Patent listings.
- Pediatric exclusivity.
- Regulatory exclusivity.
- Therapeutic-equivalence ratings for approved generics.
For a legacy product such as Vancocin, the key question is no longer whether an active brand patent blocks entry. The key question is whether any listed claim, regulatory exclusivity period or litigation order delayed a particular generic launch. Historical Orange Book entries should be reviewed together with FDA approval letters and court records.
Which companies challenged Vancocin exclusivity?
Competition came from generic manufacturers that pursued ANDAs for oral vancomycin hydrochloride capsules. The U.S. market included products from multiple generic and specialty pharmaceutical companies over time, including firms such as Teva, Par Pharmaceutical, and other FDA-approved suppliers.
The competitive field changed because:
- The product had an established reference standard.
- The active ingredient was off-patent or subject to limited remaining patent protection.
- Clinical development costs were lower under the ANDA pathway.
- Hospitals and pharmacies could substitute therapeutically equivalent products.
- Payers had strong incentives to favor lower-cost generic capsules.
The identity of the first commercial entrant and the dates of individual ANDA launches should be separated from FDA approval dates. FDA approval establishes legal marketing authorization. It does not prove that the product was immediately sold at scale.
What was ViroPharma's financial trajectory for Vancocin?
Vancocin was a major revenue contributor to ViroPharma before generic erosion. Its financial profile changed from a high-margin specialty product to a declining legacy asset.
ViroPharma's filings described a material reduction in Vancocin sales after generic oral vancomycin entered the market. The decline reflected both lower unit volume and lower net pricing. The company increasingly relied on Cinryze, an inherited C1 esterase inhibitor used for hereditary angioedema, and on pipeline assets.
| Financial phase | Vancocin economics | Strategic position |
|---|---|---|
| Pre-generic period | High-margin branded sales with limited direct competition | Core revenue engine |
| Initial generic period | Rapid volume loss and discounting | Declining cash generator |
| Mature generic period | Limited branded contribution | Legacy product |
| Post-Shire acquisition | No independent ViroPharma growth thesis | Portfolio asset within Shire |
Public company disclosures reported Vancocin net product sales in the tens to hundreds of millions of dollars annually before generic competition, followed by a sharp decline after generic entry. The exact annual figures vary by reporting period, accounting presentation and whether the comparison uses gross sales, net product sales or product revenue.
The broader ViroPharma financial trajectory was clear:
- Vancocin funded corporate operations and business development before generic competition.
- Generic entry weakened the predictability of that revenue stream.
- Cinryze became the principal growth and valuation driver.
- ViroPharma was acquired by Shire in 2014 for approximately $3.5 billion, giving investors an exit before the company faced the full consequences of a mature Vancocin franchise and the risks associated with its broader portfolio.
How did generic entry affect Vancocin pricing?
Generic entry normally produces a staged decline rather than an instantaneous collapse. The first approved generic may launch at a discount to the brand, while later entrants compete more aggressively. Pharmacy benefit managers and wholesalers then increase substitution toward lower-cost products.
The likely pricing sequence for Vancocin was:
- Brand maintained premium pricing before competition.
- First generic entered with a discount.
- Additional suppliers increased rebate and price competition.
- Brand volume fell through pharmacy substitution.
- Remaining brand demand became concentrated in prescribers or institutions with product-specific preferences.
- Gross-to-net pressure increased as discounts and contracting expanded.
Oral vancomycin capsules have a relatively simple administration profile, which supports generic substitution. The product's clinical value is driven by the active ingredient and indication rather than by a complex delivery technology. That limits the ability of the brand to preserve a durable premium after patent and regulatory barriers weaken.
How does Vancocin compare with Dificid and generic vancomycin?
Dificid and generic vancomycin compete in the same C. difficile treatment market but have different commercial positions.
| Factor | Vancocin/generic vancomycin | Dificid |
|---|---|---|
| Active ingredient | Vancomycin hydrochloride | Fidaxomicin |
| Product type | Generic-dominated legacy product | Branded product |
| Development pathway | Established reference product and ANDAs | Full new-drug development |
| Price position | Generally lower | Generally higher |
| Use case | Standard treatment, including many initial episodes | Selected patients and recurrence-sensitive cases |
| Differentiation | Familiarity, availability and cost | Narrower spectrum and recurrence-related clinical profile |
| Patent risk | Primarily historical and formulation-related | More substantial branded patent and exclusivity exposure |
| Market access | Strong formulary advantage from low cost | Managed through restrictions, rebates and clinical criteria |
Generic vancomycin has cost advantages. Fidaxomicin may receive preferential positioning in cases where recurrence reduction, guideline recommendations or hospital protocols offset its higher acquisition cost. The competitive decision is therefore influenced by total treatment cost, recurrence, hospital readmission and payer policy, not only by the prescription price.
What is the FDA regulatory status of Vancocin hydrochloride?
Vancocin was approved by FDA as an oral vancomycin hydrochloride product. Generic versions are approved through ANDAs referencing the relevant reference listed drug and demonstrating pharmaceutical equivalence and bioequivalence or the applicable alternative standard.
Regulatory considerations include:
- Whether the product is approved as a capsule or another oral dosage form.
- Whether the label covers the intended C. difficile indication.
- Whether the product is therapeutically equivalent to the reference product.
- Whether an applicant has discontinued or withdrawn a product for reasons other than safety or effectiveness.
- Whether supply interruptions affect availability.
FDA approval does not guarantee continuous commercial supply. Generic markets can become concentrated when low margins cause manufacturers to withdraw, creating shortage risk even when patent barriers have disappeared.
What patent litigation and Paragraph IV risks affected Vancocin?
Paragraph IV litigation is the principal mechanism by which an ANDA applicant challenges an Orange Book-listed patent before expiration. A Paragraph IV certification states that the listed patent is invalid, unenforceable or not infringed.
For Vancocin, relevant litigation risks included:
- Whether a formulation patent covered the generic capsule.
- Whether the generic product used a non-infringing formulation.
- Whether a patent claim was invalid for obviousness or lack of written description.
- Whether the patent was properly listed.
- Whether a lawsuit triggered a 30-month stay.
- Whether the parties reached a launch settlement.
The economic importance of these cases declined once generic products entered the market and the brand lost meaningful volume. Historical settlements, if any, should be analyzed by launch date, authorized-generic terms, supply obligations and restrictions on the generic applicant. A settlement date alone does not establish the economic value transferred between the parties.
What licensing deals affected Vancocin?
Vancocin's most important transaction was the transfer of U.S. rights from Baxter to ViroPharma in 2004. The transaction allowed ViroPharma to build a specialty-pharmaceutical business around the product and later expand its portfolio through Cinryze.
The subsequent acquisition of ViroPharma by Shire in 2014 transferred the remaining Vancocin commercial assets to Shire. By that point, the product's strategic value was lower than during its branded peak because generic competition had already altered the economics.
There is no basis to treat historical licensing or acquisition value as a current indication of Vancocin's standalone commercial value. Transaction pricing reflected the full ViroPharma portfolio, particularly Cinryze and pipeline assets.
How strong is the current Vancocin patent estate?
The current branded patent estate is weak as a commercial moat because oral vancomycin is an established molecule with multiple generic competitors. Any remaining patent rights would need to cover a specific formulation, manufacturing process or method of use and would need to withstand validity and infringement challenges.
| Patent-estate factor | Assessment |
|---|---|
| Active-ingredient protection | Not a current barrier to generic entry |
| Formulation protection | Historically relevant; claim-specific |
| Method-of-use protection | Limited by label strategy and indication scope |
| Regulatory exclusivity | Expired for the legacy product |
| Manufacturing complexity | Moderate; relevant to quality and supply |
| Substitution resistance | Low to moderate |
| Brand pricing power | Low |
| Generic entry risk | Already realized |
| Current standalone brand value | Minimal |
The principal remaining moat is operational rather than patent-based. A supplier with dependable quality, validated manufacturing and strong wholesaler relationships can retain share, but it cannot rely on the former Vancocin patent position to support premium pricing.
What generic launch scenarios exist for oral vancomycin?
The U.S. market is already in the post-exclusivity phase. The relevant scenarios are therefore supply and pricing scenarios rather than first generic entry scenarios.
Low-price, multi-supplier scenario
Several manufacturers maintain approval and supply. Prices remain low, substitution is high and brand demand is limited.
Concentrated-supply scenario
One or two manufacturers dominate after other suppliers exit. Prices may rise temporarily, and hospitals may experience allocation risk.
Shortage-driven scenario
A manufacturing or quality event reduces supply. Compounded oral vancomycin or alternative products may gain temporary share. Fidaxomicin could benefit in selected patients, but its higher price limits broad substitution.
Brand re-entry scenario
A branded product could regain limited niche demand only through supply reliability, a differentiated formulation, contracting or a new indication. Recreating Vancocin's former premium would be difficult without new clinical or delivery value.
What is the commercial outlook for Vancocin hydrochloride?
Vancocin hydrochloride has no credible branded growth trajectory. The commercial market is mature, genericized and price-sensitive. Revenue opportunity is concentrated in manufacturing efficiency, reliable supply, institutional contracting and participation in a limited number of approved dosage forms.
The main market risks are:
- Continued price compression.
- Generic manufacturer exits.
- FDA manufacturing observations or recalls.
- Raw-material supply constraints.
- Clinical preference for fidaxomicin in recurrence-sensitive patients.
- Hospital purchasing consolidation.
- Reduced prescribing of vancomycin where guidelines favor fidaxomicin.
The main opportunities are:
- Contract manufacturing.
- Authorized-generic supply.
- Hospital and government tenders.
- Reliable supply during competitor shortages.
- Alternative oral dosage forms, where regulatory requirements and demand support development.
- International markets with different generic competition and reimbursement structures.
Geographic economics differ materially. U.S. sales are heavily exposed to ANDA competition and pharmacy substitution. European and other markets may use national tenders, reference pricing or hospital procurement, producing lower unit prices but different supply dynamics. Patent status and regulatory approvals must be assessed country by country.
Key Takeaways
- Vancocin hydrochloride is the legacy branded form of oral vancomycin hydrochloride.
- Its main indication is C. difficile-associated diarrhea and enterocolitis.
- ViroPharma's revenue declined sharply after FDA-approved generic capsules entered the U.S. market in the early 2010s.
- The current market is generic-dominated, with low branded pricing power.
- Historical formulation and method-of-use patents mattered, but they no longer provide a durable commercial barrier.
- The principal competitor is generic vancomycin itself; Dificid competes through clinical differentiation and recurrence-related treatment positioning.
- Current value lies in manufacturing reliability, supply continuity and contracting rather than in patent exclusivity.
- Vancocin's former financial importance was transferred into ViroPharma's broader portfolio and ultimately Shire's 2014 acquisition.
- Generic entry risk has already been realized. The remaining risks are price erosion, supplier concentration, recalls and shortages.
FAQs
Is Vancocin hydrochloride still a branded growth product?
No. The U.S. product is a mature, generic-dominated therapy. Any remaining branded sales are commercially limited.
Is oral vancomycin the same as intravenous vancomycin?
No. Oral vancomycin is used mainly for gastrointestinal infections because systemic absorption is low. Intravenous vancomycin is used for systemic bacterial infections.
Can a generic manufacturer still challenge a Vancocin patent?
A generic applicant can challenge any unexpired, properly listed patent through a Paragraph IV certification. The commercial significance depends on the remaining patent term and claim scope.
Why can oral vancomycin face shortages after patent expiry?
Low prices and thin margins can cause manufacturers to exit. A concentrated supplier base increases exposure to manufacturing failures, quality events and raw-material disruptions.
Does fidaxomicin eliminate the market for generic vancomycin?
No. Fidaxomicin competes in the same treatment market but has a higher price and is often targeted to patients or settings where its clinical profile justifies preferential use.
References
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2006). Vancocin hydrochloride approval and labeling materials. Drugs@FDA.
-
ViroPharma Inc. (2013). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
ViroPharma Inc. (2014). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Shire plc. (2014). Announcement of recommended acquisition of ViroPharma Inc. Shire plc.
-
U.S. Patent No. 6,395,752. (2002). Vancomycin compositions. U.S. Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2017). Antibacterial drug development guidance for the treatment of Clostridioides difficile infection. FDA.
-
Johnson, S., Lavergne, V., Skinner, A. M., et al. (2021). Clinical practice guideline by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America: 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases, 73(5), e1029-e1044.
More… ↓
